EquityBulls

Latest News

Keywords Selected: Tablets

Stock Report

NATCO launches Bosentan Tablets for Oral Suspension in the United States with 180-day exclusivity
Lupin launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
Shilpa Medicare announces the approval of Nor Ursodeoxycholic Acid Tablets 500 mg for the treatment of Non‐Alcoholic Fatty Liver Disease in India
Zydus receives tentative approval from USFDA for Rifaximin Tablets, 550 mg
Lupin launches Eslicarbazepine Acetate Tablets in the United States
Wanbury Limited launching two new products, Formulation - Branded Hematinic Iron tablets, WANBURY C-RED and API- KETAMINE HYDROCHLORIDE
Zydus receives final approval from USFDA for Eluxadoline Tablets, 75 mg and 100 mg
Lupin Launches Rivaroxaban Tablets USP, 2.5mg in the United States
Eugia Pharma receives USFDA Approval for Pazopanib Tablets, 200 mg
Aurobindo Pharma receives USFDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg
Alembic Pharmaceuticals announces USFDA Final Approval for Paliperidone Extended Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg
Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India
Alembic Pharmaceuticals announces USFDA Final Approval for Albendazole Tablets USP, 200 mg
Lupin Launches Mirabegron Extended-Release Tablets in the United States
Sun Pharma introduces a novel treatment, STARIZO in India for acute bacterial skin and skin structure infections
Indoco Remedies receives USFDA final ANDA approval for Lofexidine Tablets 0.18 mg with Competitive Generic Therapy designation
Alembic Pharmaceuticals announces USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg
Zydus receives final approval from USFDA for Valsartan Tablets
Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan
Zydus receives final approval from USFDA for Sacubitril and Valsartan Tablets
Zydus receives tentative approval from USFDA for Azilsartan Medoxomil Tablets, 40 mg and 80 mg
Alembic Pharmaceuticals announces USFDA Tentative Approval for Ivosidenib Tablets 250 mg
Alembic Pharmaceuticals announces USFDA Tentative Approval for Bosutinib Tablets, 100 mg and 500 mg.
Zydus receives tentative approval from USFDA for Azilsartan Medoxomil and Chlorthalidone Tablets